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Abstract
Classical homocystinuria (HCU) is the most common inborn error of metabolism
in Qatar, with an incidence of 1:1800, and is caused by the Qatari founder p.
R336C mutation in the CBS gene. This study describes the natural history and clin-
ical manifestations of HCU in the Qatari population. A single center study was per-
formed between 2016 and 2017 in 126 Qatari patients, from 82 families. Detailed
clinical and biochemical data were collected, and Stanford-Binet intelligence, qual-
ity of life and adherence to treatment assessments were conducted prospectively.
Patients were assigned to one of three groups, according to the mode of diagnosis:
(a) late diagnosis group (LDG), (b) family screening group (FSG), and (c) newborn
screening group (NSG). Of the 126 patients, 69 (55%) were in the LDG, 44 (35%)
in the NSG, and 13 (10%) in the FSG. The leading factors for diagnosis in the
LDG were ocular manifestations (49%), neurological manifestations (45%), throm-
boembolic events (4%), and hyperactivity and behavioral changes (1%). Both FSG
and NSG groups were asymptomatic at time of diagnosis.
NSG had significantly higher intelligence quotient, quality of life, and adherence
values compared with the LDG. The LDG and FSG had significantly higher methi-
onine levels than the NSG. The LDG also had significantly higher total homocyste-
ine levels than the NSG and FSG. Regression analysis confirmed these results even
when adjusting for age at diagnosis, current age, or adherence. These findings
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increase the understanding of the natural history of HCU and highlight the impor-
tance of early diagnosis and treatment.
Synopsis: A study in 126 Qatari patients with HCU, including biochemical, clini-
cal, and other key assessments, reveals that patients with a late clinical diagnosis
have a poorer outcome, hereby highlighting the importance of early diagnosis and
treatment.
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1 | INTRODUCTION
Classical homocystinuria (HCU; OMIM 236200) is an auto-
somal recessive inborn error of methionine (Met) metabo-
lism caused by deficiencies in the cystathionine beta-
synthase (CBS) enzyme, with a worldwide incidence of
approximately 1:200000 births.1,2 Although very rare else-
where, HCU is the most common metabolic disease in Qatar,
with an estimated incidence of 1:1800, the highest in the
world, making it the most prevalent inherited monogenic
disease in that nation.3,4 This high frequency is primarily
attributed to a single founder Qatari mutation, p.R336C
(c.1006C>T) (GenBank reference sequence NM_000071.2)
in the CBS gene, a missense mutation replacing arginine
(R or Arg) with cysteine (C or Cys), causing a severe vita-
min B6 nonresponsive phenotype.4,5
Clinically, untreated HCU patients exhibit multisystem
manifestations, such as ectopia lentis (dislocation of the
lens), nearsightedness, learning and intellectual disabilities
(IDs), developmental problems, osteoporosis, and skeletal
deformities. The latter include chest deformities, Marfanoid
habitus, and scoliosis. Most important, HCU patients exhibit
psychomotor retardation and life-threatening complications
of the vascular system. They are characterized biochemically
by high levels of plasma methionine (Met), as well as
plasma and urine total homocysteine (tHcy).1,6-8
In Qatar, with the advent of a national biochemical and
molecular newborn screening (NBS) program in 2006, early
detection and treatment of HCU, through administration of
Met-restricted diets and betaine, has changed the natural his-
tory of the disease.4,9,10
However, the current treatment options, based on a life-
long Met- and protein-restricted diet supplemented with
essential amino acids, are limited and difficult to maintain,
especially during puberty, adolescence, and adulthood.11
This study was conducted to delineate the clinical pheno-
types, as well as their progressions and correlations with
stage of diagnosis, in the homogenous Qatari population of
vitamin B6 nonresponsive HCU caused by a single founder
Qatari mutation (p.R336C).
2 | METHODS
A single center study (Clinical and Metabolic Genetic Divi-
sion, Pediatrics Department, Hamad Medical Corporation,
Doha, Qatar) was performed between 2016 and 2017 in
patients with HCU. Detailed clinical and biochemical data
were retrospectively collected. Stanford-Binet intelligence,
quality of life (PedsQL) and adherence to treatment
(Morisky scale) assessments were performed prospectively.
A questionnaire survey was developed at Hamad Medical
Corporation and approved by Medical Research Center (see
Ethics section). The questionnaire survey was filled out by
the clinicians and consisted of four parts:
•Part one. The detailed natural history of HCU due to
CBS deficiency in Qatari patients was documented and phe-
notypic diversity in both late and early diagnosed individuals
was delineated. Information collected for each subject
included: demographic data, assessment of anthropometric
measurements (especially arm span-to-height and upper-to-
lower segment ratios), detailed medical history (including a
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three generation family history, course of the disease and
any short- and long-term complications), as well as bio-
chemical and radiological data. The natural history data were
collected from patient files and, for any information not
available in these files, from interviews of adult cases or par-
ents of pediatric patients, as appropriate.
•Part two. Cognitive function was assessed in the
enrolled patients using the Stanford-Binet Intelligence Scale
(Versions 4 and 5), adopted from Child Development Center
at Rumailah Hospital, administered only to those patients
aged ≥3 years. The Stanford-Binet test is a cognitive ability
assessment for measuring intelligence quotient (IQ). It
assesses five domains of cognitive ability: fluid reasoning,
knowledge, quantitative reasoning, visual-spatial processing,
and working memory. Each of these factors is tested in two
separate domains, verbal and nonverbal, yielding an IQ
score.
•Part three. A measure of patient well-being was
obtained with a quality of life (QoL) assessment, using
the English and Arabic versions of PedsQL 4.0, adminis-
tered only to patients ≥2 years old. For pediatric patients
(aged ≤5 years), these were proxy reports and, for all
others, they were self-reports. This method is considered
effective and beneficial in Qatar for evaluating QoL in
patients with HCU undergoing special dietary treatment
and for determining psychosocial support needs for these
patients and their families. The test uses four subjective
QoL domains: emotional, physical, social, and cognitive
function.
•Part four. Patient adherence/compliance to pharma-
cological and dietary management was assessed using the
9-item Morisky Medication Adherence Scale (9-MMAS).
The pharmacological and dietary management parts of
the questionnaire consisted of two sections:
(a) administration of an assessment adapted from the
well-validated Morisky-Green test and the 8-item
MMAS. This adaptation was described previously.12,13
The resulting 9-MMAS included nine items measuring
the presence or absence of nonadherent behaviors. In our
study, good adherence was defined by a Morisky score of
11 or higher (ie, ≥85%). This cutoff was selected based
on previous reports.14,15 (b) Patients were asked
predefined follow-up questions to identify potential fac-
tors known to influence adherence to diet and treatment.
These questions were related to patient lifestyle, income,
and other treatment-related factors (eg, degree of social
support, knowledge about treatment, and accessibility of
the treating clinic). All procedures followed in this study
were in accordance with the ethical standards of the
responsible committee on human experimentation (insti-
tutional and national) and with the Helsinki Declaration
of 1975, as revised in 2000.
3 | BIOCHEMICAL ANALYSIS
NBS for HCU is based on measuring tHcy and Met from
dried blood spots.9,11,16
4 | MUTATION ANALYSIS
CBS gene genotyping was performed using real-time poly-
merase chain reaction or DNA sequencing, as part of the
clinical practice.4,5
5 | PATIENTS' CLASSIFICATION
Patients were assigned to one of three groups according to
mode of diagnosis/screening time: (a) late diagnosis group
(LDG): symptomatic patients born primarily before the
availability of the national NBS program; (b) family screen-
ing group (FSG): asymptomatic patients diagnosed because
of a positive family history; and (c) newborn screening
group (NSG): asymptomatic patients diagnosed by NBS.
6 | STATISTICAL ANALYSES
Descriptive statistics in the form of median, mean, range,
and frequency, with percentages, were calculated.
Kaplan-Meier curves were constructed to assess differ-
ences in medians, among the three groups, of ocular mani-
festations and of survival. A log rank (Mantel Cox) test was
used to assess this difference, with a two-tailed P-value <.05
regarded as statistically significant.
One-way analysis of variance (ANOVA) and the
Bonferroni post-hoc test were conducted to assess differences
among the three predictor groups (screening groups: NSG,
FSG, and LDG) in relation to the different outcomes (IQ,
QoL, Met tHcy, and adherence), with a P-value (two-tailed)
<.05 considered to be statistically significant.
Pearson correlation analysis was performed among all vari-
ables to measure the strengths of their relationships. In addition,
a partial correlation analysis was performed, adjusting first for
current age only and then for age at diagnosis only. Strengths
of these correlations (r) are reported along with the P-values.
Multiple linear regression analyses were conducted to test
whether screening time (NSG, FSG, and LDG) (independent
variable: IV) would predict psychological and medical fac-
tors, that is, IQ, QoL, Met, tHcy, and adherence (dependent
variable: DV), before and after adjusting for current age
and/or age at diagnosis (using separate regression models:
with current age only, age at diagnosis only, and both cur-
rent age and age at diagnosis). Linear regression models
were also performed for screening time as IV, while
adjusting for adherence, to predict different DVs. The
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B value, which represents the strength and direction of the
prediction along with the P-value and adjusted R2 (indicat-
ing how much is explained by each prediction model) are
reported for each regression analysis.
Multinomial logistic regression was used to test the
strength of prediction for screening time (IV) (employing a
reference group for comparisons among the three groups) in
relation to the categorical variable adherence (differences for
two categories). This was done before and after adjusting for
confounder variables (current age or/and age at diagnosis).
All P-values presented are two-tailed, and P-values <.05
were considered to be statistically significant.
All statistical analyses were performed using the statisti-
cal package SPSS 24.0 (SPSS Inc., Chicago, Illinois).
7 | RESULTS
7.1 | Patient demographic data
The total sample included 131 patients, out of which, five
patients were excluded from the study (three with different
mutations, one with Down syndrome, and one who did not
follow up after the first visit).
Thus, the final sample included 126 patients with HCU
(54 female, 72 male, current age: 1 to 41 years, mean:
17.41 years, SD: 10.24), from 82 families. HCU diagnosis
was confirmed by elevated plasma tHcy and Met levels and
the presence of homozygous p.R336C founder mutation
(age at diagnosis: 2 weeks-20 years, mean: 4.30 years,
SD: 4.46).
Of the 126 patients enrolled, 69 (55%) were in the LDG
(age at diagnosis: mean: 7.5 years), 13 (10%) in the FSG
(age at diagnosis: mean: 2 years), and 44 (35%) in the NSG
(age at diagnosis: mean: 2 weeks) (see the next section,
“Main and associated clinical manifestations,” for more
details). All subjects in the study were followed regularly for
at least 24 months. At enrollment, patients ranged in age
from 5 to 41 years (mean: 24.54, SD: 7.19) in the LDG,
from 13 to 30 years (mean: 16.88, SD: 4.77) in the FSG, and
from 1 to 13 years (mean: 6.39, SD: 3.2) in the NSG
(Table 1).
TABLE 1 Summary information for the three patient groups
Late diagnosis group Family screening group Newborn screening group
N: 126a 69 13 44
Age at diagnosis (median, range) 7 years (1 to 20 years) 1 year (1 month to 5 years) 2 weeks (2 weeks to 1 month)
Age at recruitment into study (median, range) 24 years (5 to 41 years) 14.5 years (13 to 30 years) 6.2 years (1 to 13 years)
Conditions at diagnosis
Ocular 49% N/A N/A
Intellectual disability 42% N/A N/A
Thromboembolic 4% N/A N/A
Behavior 1% N/A N/A
Seizures 3% N/A N/A
Bone N/A N/A N/A
Clinical symptoms during course of disease
Ocular 92% 30% N/A
Intellectual disability 79% N/A N/A
Cardiovascular abnormalities 29% 7.6% N/A
Psychiatric 22% 7.6% 22.7%
Marfanoid habitus 98.5% 49% 7%
Scoliosis 51% 15% N/A
Adherence to diet 15.6% 38.5% 61.4%
Total homocysteine levels, μmol/L (median,
range)
108 (42-363) 77.61 (31-102) 52.23 (19-130)
Methionine levels, μmol/L (median, range) 829 (231-1524) 875 (632-1044) 381(20-1029)
IQ (median, range) 79.00 (39-113) 97.00 (89-110) 98.50 (84-116)
Quality of life (median, range) 86.25 (13-95) 91.25 (65-98) 97.50 (88-100)
aFive patients (4%) died (1 dying at 3 years of age in a car accident and the other 4 during adulthood from thromboembolic events). Data was available for all 126
enrolled patients.
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Consanguinity was found in 124 (98.4%) patients,
74 (60%) were first cousins and the remaining were either
second cousins or from the same tribe.
There were 118 (94%) Qatari patients, with the remaining
8 (6%) patients from the Gulf Cooperation Council. All
patients belonged to the same tribe and had the same founder
(p.R336C) mutation.
Regarding education level, approximately 50% of the
LDG group were either illiterate or attended a special school
for the blind due to the serious ocular abnormalities associ-
ated with HCU, while patients in the NSG and FSG attended
a regular school.
8 | MAIN AND ASSOCIATED
CLINICAL MANIFESTATIONS
Patients in the LDG. The major factors leading to diagnosis
were ocular manifestations in 34 (49%), neurological mani-
festations in 31 (45%), thromboembolic events in 3 (4%),
and psychiatric manifestations in 1 (2%) (Tables 2 and S1).
The median age for ocular manifestations was 7.5 years and,
of the 34 patients, 29 (85%) had ectopic lentis (EL), 1 (3%)
myopia, 3 (9%) EL plus secondary glaucoma, and 1 (3%) EL
plus cataract.
The median age for neurological manifestations was
6 years and, of the 31 patients, 29 (94%) had ID and 2 (6%)
had seizures. Of those patients with ocular manifestations as
the major factors leading to diagnosis, 28 (82%) also had
TABLE 2 Clinical features leading to diagnosis of classical
homocystinuria in the late diagnosis group
Clinical features
Primary cause
of diagnosis
(% of patients)
Contributory
cause (% of
patients)
Ocular manifestations 49 58
Neurological manifestations 45 82
Thromboembolic events 4 0
Psychiatric manifestations 2 0
Musculoskeletal
manifestations
0 7
Fair hair and skin 0 14
TABLE 3 Complications in the late diagnosis group during disease progression
Category Complication
Number of
patients
Onset at
<18 years
Onset at
≥18 years
Skeletal Marfanoid habitus 68 40 28
Scoliosis 35 22 13
Back pain, knee pain, neck pain or osteoporosis 38 17 21
Fracture 20 16 4
Otherb 3 2 1
Central Nervous System
(CNS)
Intellectual disability 49 49 None
Learning disability 60 13 47
Seizure 10 10 None
White matter changes detected in head magnetic
resonance imaging or computed tomography
scan
13 7 6
Other (extrapyramidal symptoms) 2 None 2
Cardiovascular All 20 10 10
Psychiatric Aggression or/and behavioral abnormalities 56 12 44
Other psychiatric disorders 15 7 8
Ocular Myopia 13 13 None
Lens dislocation 61 54 1
Eye surgery 41 35 6
Other complications in ectopic lentis, for example,
cataract and glaucoma
20 18 2
Rarea All 32 20 12
aRare hypertension (14%), fatty liver (7%), skin disorders (6%), bronchiectasis (4%), chronic pancreatitis (4%), and gastrointestinal bleeding (1%).
bOther (degenerative lumbar disc disease with spondylolisthesis and pars defect at 38 years, two below 18 years presented with osteolytic lesion suggestive of
nonossifying fibroma and other with cystic sclerotic lesions and periosteal reaction suspected Ewing's sarcoma).
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associated neurological manifestations such as ID or seizures
and 1 (3%) had musculoskeletal manifestations (Table 2).
Of those patients with neurological manifestations as the
major factors leading to diagnosis, 18 (58%) also had associ-
ated ocular manifestation such as myopia and EL, and
3 (7%) had musculoskeletal abnormalities such as skeletal
deformities (Table 2).
Other associated clinical manifestations at the time of
diagnosis were fair hair and skin in 10 (14%) patients.
The following complications were observed in the LDG:
98.5% with Marfanoid habitus, 92% ocular abnormalities,
79% ID, 51% scoliosis, 29% fractures, 29% cardiovascular
abnormalities, and 22% psychiatric illnesses. In addition, 6%
developed severe thromboembolic events, leading to death
in adulthood (Table 3).
Other complications included hypertension (14%), fatty
liver (7%), skin disorders (6%), bronchiectasis (4%), chronic
pancreatitis (4%), and gastrointestinal bleeding (1%)
(Table 3).
Patients in the FSG. All patients in this group were
asymptomatic at the time of diagnosis. However, during
course of their disease, 49% developed mild Marfanoid habi-
tus, 15% scoliosis, 30% ocular complications, 15% chronic
pancreatitis, and 8% mitral valve prolapse (Table S2).
Patients in the NSG. The mean age of diagnosis and initi-
ation of treatment was approximately 2 weeks. During the
course of their disease, 22.7% of patients developed behav-
ioral manifestations and 7% developed Marfanoid habitus
(Table 1). As previously reported, NBS was performed
based on blood tHcy levels.9
Comparison of ocular manifestations among groups.
Kaplan-Meier analyses (Figure 1) showed significant differ-
ences among groups in incidence of ocular symptoms during
the course of disease, with such manifestations observed in
92% of the LDG, 30% of the FSG, and none of the NSG
patients (P ≤ .001).
A survival analysis was not feasible because of the rel-
atively low mortality exhibited in the LDG group during
the study, with 85% of patients still alive at age 31 years.
No mortality associated with HCU was observed in the
NSG or FSG. Thus, without a longer duration follow-up,
survival differences among the three groups could not be
assessed.
9 | DIFFERENCES AMONG THE
SCREENING TIME GROUPS IN
PSYCHOLOGICAL FACTORS,
ADHERENCE, AND BIOCHEMICAL
PROFILES
IQ. The IQ test was administered to 89 (70%) of the patients.
Of those not tested for IQ, 21 (17%) refused, 11 (10%)
were < 3 years old, and 5 (4%) had died earlier in the study.
The IQ test was, therefore, administered to 52 patients from
the LDG, 9 from the FSG, and 28 from the NSG (Table 4).
FIGURE 1 Kaplan-Meier curves
showing onset of ocular symptoms
amongst NSG, FSG and LDG
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Quality of life (QoL). The QoL test was adminis-
tered to a total of 107 patients, from the LDG (n = 60),
FSG (n = 13), and NSG (n = 34). Of the 19 individuals
not tested, 9 were younger than 2 years old, 5 had died,
and 4 (all from the LDG) refused to participate
(Table 4).
Patients' adherence. Patients' adherence was assessed for
120, from the LDG (n = 64), FSG (n = 13), and NSG
(n = 44). Adherence scores ranged from 3 to 13 (median 10)
(Morisky scores: nonadherence: <11; adherence: ≥11)
(Table 4).
Biochemical profiles, based on sulfur metabolite levels.
Plasma metabolite levels were determined for 124 patients,
including 67 subjects from the LDG, 13 from the FSG, and
44 from the NSG.
One-way ANOVA was conducted to compare the three
screening time groups in relation to the different outcomes. The
analysis indicated significant differences among the
screening time groups (NSG, FSG, and LDG) for IQ (F(2, 86)
= 32.69; P ≤ .001; η2 = .432), QoL (F(2, 104) = 18.15;
P ≤ .001; η2 = .259), Met levels (F(2, 121) = 36.63;
P ≤ .001; η2 = .377), tHcy levels (F(2, 121) = 20.84; P ≤ .001;
η2 = .256), and adherence to diet and medication (F(2, 118)
= 18.30; P ≤ .001; η2 = .237).
Bonferroni post-hoc test results indicated that the NSG
had significantly higher IQ, QoL, and adherence values
compared with the LDG (P ≤ .001). In addition, the FSG
had significantly higher IQ values than the LDG
(P ≤ .001). The LDG and FSG had significantly higher
Met levels than the NSG (P ≤ .001). The LDG also had
significantly higher tHcy levels than the NSG (P ≤ .001)
and FSG (P = .006).
We characterized adherence to diet and medications
into two categories: adherent (cutoff ≥ 11) and non-
adherent (<11). There was a significant relationship
between adherence and screening time groups
(χ2(2, N = 121) = 24.16, P ≤ .001). Patients in the NSG
were more likely to be in the adherent category (N:
27/44 = 61.4%), compared with those in the FSG (N:
5/13; 38.5%) or LDG (N: 10/64; 15.6%). Cumulatively,
therefore, the earlier the diagnosis, the more likely a
patient would be adherent.
TABLE 4 IQ, QoL, adherence, Met level, and total homocysteine level values in different screening time groups and in all patients
Outcomes Groups No Mean SD SE
95% confidence interval
for mean Range
Minimum Maximum Minimum Maximum
IQ NSG 28 99.89 8.689 1.642 96.52 103.26 84 116
FSG 9 98.11 8.313 2.771 91.72 104.50 89 110
LDG 52 80.31 12.420 1.722 76.85 83.77 39 113
Total 89 88.27 14.464 1.533 85.22 91.32
QoL NSG 34 96.52 3.626 0.622 95.26 97.79 88 100
FSG 13 89.81 8.424 2.336 84.72 94.90 65 98
LDG 60 82.62 13.589 1.754 79.11 86.13 13 95
Total 107 87.91 12.450 1.204 85.52 90.30
Adherence NSG 44 10.4318 2.32677 0.35077 9.7244 11.1392 5.00 13.00
FSG 13 9.0000 2.91548 0.80861 7.2382 10.7618 2.00 12.00
LDG 64 7.1406 3.04916 0.38114 6.3790 7.9023 2.00 13.00
Total 121 8.5372 3.17028 0.28821 7.9666 9.1078
Met NSG 44 388.17 277.006 41.760 303.95 472.39 20 1029
FSG 13 852.45 138.323 38.364 768.86 936.03 632 1044
LDG 67 815.93 283.748 34.665 746.71 885.14 231 1524
Total 124 667.97 339.736 30.509 607.58 728.36
Total homocysteine NSG 44 61.19 28.306 4.267 52.58 69.79 19 130
FSG 13 73.51 23.359 6.479 59.39 87.63 31 102
LDG 67 119.76 60.493 7.390 105.01 134.52 42 363
Total 124 94.13 55.569 4.339 85.54 102.72
Abbreviations: FSG, family screening group; IQ, intelligence quotient; LDG, XXX; met, methionine; NBS, newborn screening; QoL, quality of life.
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10 | CORRELATIONS BETWEEN
SCREENING TIME AND THE
MEDICAL AND PSYCHOLOGICAL
FACTORS
Screening time with other factors. There was a significant
negative correlation between screening time and IQ (r =
−.636, n = 89, P ≤ .001) (strong), QoL (r = −.509,
n = 107, P ≤ .001) (moderate), and adherence (r = −.486,
n = 121, P ≤ .001) (moderate). These results indicated that
the earlier the screening time, the higher the IQ, QoL, and
adherence. Screening time also had significant positive cor-
relations with plasma levels of Met (r = .571, n = 124,
P ≤ .001) and tHcy (r = .497, n = 124, P ≤ .001). Thus, the
higher the screening time, the more abnormal biochemical
profile. Adjusted for current age, the correlations between
screening time and IQ (r = −.268, P = .012), adherence
(r = −.211, P = .022), Met levels (r = .299, P = .001), and
tHcy (r = .300, P = .001) became weaker but were still sig-
nificant, while for QoL the correlation became
nonsignificant.
When adjusted for age at diagnosis, correlations between
screening time and adherence (r = −.272, P = .003), IQ
(r = −.381, P ≤ .001), QoL (r = −.310, P ≤ .001), Met
(r = .505, P ≤ .001), and tHcy (r = .296, P = .001) also
were weaker than for nonadjusted values, but still
significant.
Adherence with other factors. There was a significant
positive correlation between adherence and both IQ
(r = .302, n = 88, P = .004) and QoL (r = .252, n = 106,
P = .009). The higher the adherence, the higher the IQ and
QoL. In contrast, adherence was negatively correlated with
plasma levels of Met (r = −.357, n = 121, P ≤ .001) and
tHcy (r = −.548, n = 121, P ≤ .001). Thus, with lower
adherence, metabolic abnormalities were higher. Only the
correlation between adherence and tHcy levels remained sig-
nificant when data were adjusted for current age (r = −.438,
P ≤ .001) or age at diagnosis (r = −.452, P ≤ .001). The
correlation of adherence with Met levels (r = −.246,
P = .007) remained significant also when data were adjusted
for age at diagnosis.
QoL and IQ with other factors. There was a significant
positive correlation between QoL and IQ (r = .638, n = 88,
P ≤ .001). There were significant negative correlations
between QoL and Met levels (r = −.195, n = 106,
P = .045), QoL and tHcy levels (r = −.302, n = 106,
P = .002), IQ and Met levels (r = −.340, n = 88, P = .001)
and IQ and tHcy levels (r = −.376, n = 88, P ≤ .001). How-
ever, only the correlation between QoL and IQ remained sig-
nificant when data were adjusted for current age (r = .452,
P ≤ .001) or age at diagnosis (r = .533, P ≤ .001).
11 | SCREENING TIME
PREDICTING PSYCHOLOGICAL
AND MEDICAL FACTORS BEFORE
AND AFTER ADJUSTING FOR
CURRENT AGE AND/OR AGE AT
DIAGNOSIS
Linear regression analyses were conducted to test whether
screening time (in the NSG, FSG, and LDG) predicted psy-
chological and medical factors, with or without adjusting
data for current age or age at diagnosis.
Without age-related adjustments, the regression model
was significant for QoL (F(1, 105) = 36.63, R2 = .259;
P ≤ .001), IQ (F(1, 87) = 58.97, R2 = .404; P ≤ .001), adher-
ence (F(1, 119) = 36.82, R2 = .236; P ≤ .001), plasma Met
levels (F(1122) = 58.99, R2 = .326; P ≤ .001), and plasma
tHcy levels (F(1, 122) = 40.10, R2 = .247; P ≤ .001).
Screening time predicted QoL (B = −6.96, P ≤ .001), IQ
(B = −10.06, P ≤ .001), adherence (B = −1.65, P ≤ .001),
Met levels (B = 208.22, P ≤ .001), and tHcy levels
(B = 29.67, P ≤ .001).
With data adjusted for age at diagnosis, the prediction
model for screening time indicated significance for QoL
(B = −6.149, R2 = .418, P = .001), IQ (B = −7.863,
R2 = .289, P ≤ .001), adherence (B = −1.44, R2 = .252,
P = .001), Met levels (B = 275.44, R2 = .348, P ≤ .001),
and tHcy levels (B = 25.69, R2 = .250, P ≤ .001).
These results indicated that age at diagnosis did not
explain the relationship between screening time and QoL,
IQ, adherence, Met levels, or tHcy levels.
From the adjusted variable, the age at diagnosis was a
significant predictor only for Met levels (B = −17.96,
P = .047), when considering the screening time.
When data were adjusted for current age, the prediction
model for screening time indicated significance for IQ (B =
−5.777, R2 = .447, P = .007), adherence (B = −1.020,
R2 = .253, P = .030), Met levels (B = 163.69, R2 = .333,
P = .001), and tHcy levels (B = 28.56, R2 = .248,
P = .001). In contrast, with this adjustment, there was no
longer significance in the prediction model for QoL (B =
−2.832, R2 = .315, P = .118). Thus, current age explained
the relationships between screening time and QoL, but not
those between screening time and IQ, adherence, Met, or
tHcy levels.
From the adjusted variable, current age was a sig-
nificant predictor for IQ (B = −0.505, P = .011) and
QoL (B = −0.492, P = .004), when considering the
screening time.
With adjustments for both current age and age at diagno-
sis, the prediction model for screening time showed no sig-
nificance for all DVs, except Met levels (B = 219.19,
R2 = .368, P ≤ .001) and tHcy (B = 26.02, R2 = .250,
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P = .005). This indicated that current age and age at diagno-
sis explained the relationship between screening time and
most of the DVs, except Met and tHcy levels. From the
adjusted variable, current age was a significant predictor for
IQ (B = −0.470, P = .032) and QoL (B = −0.520,
P = .005) when considering screening time and age at diag-
nosis, while age at diagnosis was a significant predictor for
Met levels (B = −23.97, P = .012) when considering
screening time and current age.
We constructed a new model using screening time and
adherence to predict IQ, QoL, Met levels, and tHcy levels.
The prediction model for screening time indicated signifi-
cance for QoL (B = −6.369, R2 = .271, P ≤ .001), IQ (B =
−9.659, R2 = .402, P ≤ .001), Met (B = 195, R2 = .346,
P ≤ .001), and tHcy levels (B = 17.59, R2 = .374,
P ≤ .001). Adherence was also significantly related to tHcy
levels (B = −6.61, R2 = .374, P ≤ .001), with adjustment
for screening time. This indicated that adherence did not
explain relationships with any DV.
We then employed multinomial logistic regression with
adherence to diet and medications (adherent: cutoff
point ≥ 11 and nonadherent: <11) as the DV and screening
time as the IV. The prediction model indicated significance
(χ2(2, N = 121) = 24.74, P ≤ .001). Results indicated that
patients in the NSG were more likely to be in the adherent
category than were those in the LDG (odds ratio: 8.58, 95%
confidence interval [CI]: 3.46-21.25), with no significant dif-
ferences between NSG and FSG, or between FSG and LDG.
With adjustments for current age and/or age at diagnosis,
there was no longer a significant difference between the
NSG and LDG, relative to adherence.
12 | DISCUSSION
This study supports a close association between age of diag-
nosis and the outcome of HCU severity. In particular, early
detection by NBS (patients in the NSG), leading to early ini-
tiation of treatment, was associated with a markedly less
severe disease course. In contrast, patients in the LDG, diag-
nosed between ages 1 and 20 years (median 7 years old),
and recruited into the study at ages 5 to 41 years (median
24 years), presented with a variety of serious manifestations,
primarily ocular or neurological, along with numerous asso-
ciated symptoms including skeletal abnormalities. The con-
stellation of symptoms experienced by these patients is what
ultimately led to their diagnosis of HCU. The NSG patients,
with all 44 patients in the study diagnosed at approximately
2 weeks of age, exhibited no primary or associated clinical
presentations at diagnosis. Fourteen NSG patients developed
symptoms, especially aggressiveness and hyperactive behav-
iors, as their disease progressed, but no ocular symptoms or
ID occurred in this subcohort by the end of this study. These
patients were recruited into the study at ages ranging from
2 weeks to 13 years old (median, 6 years old) and were,
therefore, younger than the other groups during the study.
The median age of the NSG cohort (6 years) is similar to
the median age when LDG patients were first diagnosed
(7 years). However, children in the NSG had far fewer com-
plications upon diagnosis than did those in the LDG.
Although about 22.7% (10) of NSG patients developed
behavioral manifestations, during the time covered by this
study they did not develop other disabilities, including ocu-
lar or IDs, the primary diagnoses of patients in the LDG.
Our results were consistent with those from a long-term
retrospective study in Ireland of 25 patients under age
24 with HCU, bearing the Irish mutation p.I278T. That pre-
vious study suggested that lens dislocation could be
prevented, or at least significantly delayed, in patients whose
tHcy levels were consistently decreased from an early age.
Early Hcy-lowering treatment was also associated with a
reduced risk of overall ocular complications, including wors-
ening myopia.17
More recent data from the Irish NBS program was used
to compare the mental capabilities of 23 pyridoxine non-
responsive individuals with HCU with those of 10 unaffected
sibling controls.18 Of the 23 patients identified, 19 were
diagnosed with HCU through NBS and treated early in life
(within 6 weeks of birth), two cases were detected late (age
2 years), and two had been untreated at the time of assess-
ment. Overall, 13 of the 19 patients in the early treated group
(mean age 14 years; range 4 to 25) were compliant with
treatment and had no complications, whereas the remaining
6 (mean age 20 years; range 14 to 26), who had poor com-
pliance, developed complications. Mean full-scale IQ was
normal in the compliant group but low in the poorly compli-
ant and noncompliant groups.18 Despite the relatively small
numbers, these results suggested that early treatment with
good biochemical control prevented mental retardation and
our study confirmed the findings from this Irish cohort.
The IQ results in our study illustrated that those in the
LDG had more intellectual deficits than did those in the
other two groups. The mean IQ score in the LDG was signif-
icantly lower than in the NSG or FSG. Similarly, in an ear-
lier study utilizing healthy siblings as controls, showed that
patients diagnosed by NBS had better developmental and
cognitive outcomes than did those diagnosed later.19 These
results remained significant in the correlation analysis even
when we adjusted for current age and age at diagnosis.
Our study, unlike previous studies, included bigger sam-
ple size in each group and we were able to compare the
results to the FSG. In addition, we also found that LDG has
lower QoL compared to NSG. This is related to impairments
in different domains including physical, emotional, social,
and school. This indicates that early screening can detect
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problems early on, and thus provide patients with suitable
early treatment and interventions. These results remained
significant when adjusting for age at diagnosis but dis-
appeared when adjusting for current age. This means that
patients' current age determined differences in QoL levels.
The benefits of Hcy-lowering therapy in individuals with
psychiatric symptoms associated with HCU were first dem-
onstrated in a study of 12 late-diagnosed patients.20 Three of
these patients were never treated effectively and had serious
psychological disorders, with premature deaths. The
remaining 8 patients ranged from 1 to 26 years of age (mean
13 years) had psychiatric symptoms, including irritability,
attention deficit hyperactivity disorder, apathy, and psycho-
sis. Treatment was associated with a striking improvement
in behavior and intellectual development, correlating with
biochemical normalization.
In our study NSG had lower biochemical levels (Hcy and
Met levels) compared to the LDG and also lower levels of
Met compared to FSG. These results are also reflected and
strongly related to adherence to medical therapy and diet by
our participants in this study. The results in relation to bio-
chemical and adherence levels remained significant even
when adjusting for current age or age at diagnosis. This
means that early screening itself led to better adherence to
therapy and diet regardless of the age of the patient and thus
better biochemical levels.
Regarding compliance with medical therapy, the propor-
tion of adherent to nonadherent patients was 1:6.4 in the
LDG, 1:2.6 in the FSG, and 1.6:1 in the NSG. The age at
which the patients were diagnosed was strongly correlated
with compliance, with the group diagnosed latest (LDG)
being the least compliant. However, it must be noted that
most patients in the FSG, similar to those in the NSG, were
diagnosed in infancy and, yet, those in the FSG were less
compliant than those in the NSG. This is likely attributable
to patients in the FSG being older, on average, during the
study, and illustrates how difficult compliance can be to
achieve once the individual has been exposed to normal pro-
tein foods, even in infancy, and how increasingly difficult it
becomes for patients to remain adherent at ages beyond
childhood.
In this study, we found significant positive correlations
between adherence and both IQ and QoL, which disappeared
when adjusting for age at diagnosis or current age. In con-
trast, adherence was negatively correlated with plasma levels
of Met and tHcy even when adjusting for age at diagnosis.
tHcy also remained significant when adjusting for
current age.
Regression analysis supports this and gave a new
insight into these relationships. High adherence was sig-
nificantly related to lower tHcy levels, with adjustment
for screening time.
Compliance with medical therapy was poorer in the LDG
and the disease progressed markedly in these patients, with
additional adverse manifestations developing in the years
following their diagnosis. In contrast, patients in the FSG,
identified based on family history of HCU, were diagnosed
earlier than those in the LDG, at ≤5 years of age (median
2 years), and initially presented with no clinical manifesta-
tions. However, as their disease progressed, they developed
many symptoms similar to those in the LDG. They were rec-
ruited into the study at 12 to 29 years old (median 13 years
old). Only two patients in the FSG had not yet developed
any HCU-related clinical manifestations by the time this
study was performed, and these two children were among
the youngest in this group. A combination of lack of adher-
ence to treatment and thus cumulative effects of exposure to
abnormally high tHcy and Met levels likely led to these poor
outcomes. Of note, even patients with excellent adherence to
treatment could not achieve normalization of tHcy levels.
This was not related to age at diagnosis or/and current age.
Although a restricted diet decreases tHcy levels in fully
compliant patients to varying degrees, many patients never
achieve normalization.11 Treatment must be continued
throughout life, as periods of poor metabolic control have
cumulative deleterious effects that can lead to severe compli-
cations and premature death. However, compliance with diet
is often poor because of the complexities of the diets and
their severe restrictions.21 Adherence generally deteriorates
during adolescence and adulthood22,23 and can be particu-
larly challenging for patients with a late diagnosis.24 Overall,
in our study, patients in the NSG were under better meta-
bolic control than those in the other groups, consistent with
their higher compliance. However, all groups had median
tHcy levels substantially higher than normal values
(≤15 μmol/L).17 Patients in the LDG and FSG groups also
had higher Met levels than did those in the NSG.
The patients in NSG and FSG, although on average diag-
nosed only a few months apart, showed marked differences
in adherence to treatment and in clinical manifestations.
These treatments varied among patients, with most pre-
scribed a low protein diet only while others receiving addi-
tional betaine supplementation. These differences in clinical
manifestations were likely due to lower adherence to treat-
ment and higher ages, as the mean age of patients in the
FSG was older than that of patients in the NSG. This lower
adherence was possibly compounded by the initial difficulty
for patients of accepting the low protein diet after having
been introduced to foods with standard protein contents.
Age is a known risk factor for lack of compliance in
adolescents,22,23 and years of exposure to abnormally high
tHcy levels likely contributed to cumulative damage.
Consistent with the course of disease progression, plasma
tHcy and Met levels indicated greater metabolic control in
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the NSG than in the FSG and, even more so, than in the
LDG. Some of these differences in disease severity might be
related to the discrepancies in compliance with treatment
observed among the three groups, leading to the higher tHcy
levels. Adherence to treatment was inversely correlated with
age of diagnosis, with the group diagnosed at birth achieving
the highest compliance to treatment. In the NSG, FSG, and
LDG, approximately 61%, 39%, and 15%, respectively, were
identified as fully adherent to treatment. This was consistent
with the general knowledge that dietary compliance becomes
more challenging in adolescent and adult patients, as com-
pared with in young children.22,23 Thus, the older ages of
patients in the FSG at study enrollment may partially
account for the poorer metabolic control, compared with
those in the NSG. It was notable that, despite the high com-
pliance in the NSG, plasma tHcy levels were still well above
normal and, as the disease progressed, several clinical mani-
festations, especially aggressive or hyperactive behavior,
were noted in a substantial percentage of patients aged 3 to
11 years. It should be noted that patients in the NSG ranged
in age from 1 to 13 years, and it is conceivable that addi-
tional clinical manifestations of the disease may appear as
this patient group ages further, including cumulative damage
from elevated tHcy levels.
This study was conducted in Qatar, where the incidence
of HCU is extremely high, attributed primarily to parental
consanguinity and caused by a single founder mutation in
the CBS gene, p.R336C.4,5 Indeed, about 99% of the patients
enrolled in our study were from consanguineous families. It
might be suggested that such unique aspects of this patient
population would limit extrapolation of these findings to the
broader worldwide population of HCU sufferers. Nonethe-
less, these patients, especially those in the LDG and FSG
groups, exhibited an array of severe multisystem complica-
tions characteristic of HCU caused by other CBS mutations.2
Furthermore, the importance of early diagnosis and the
adverse impacts of inconsistent treatment compliance
observed here were also supported by several other stud-
ies17,18 performed in various patient populations.
The regression analysis in this study confirms these
results by giving predictions models and the strength for
each. We found that late screening time predicts lower QoL,
IQ, adherence, and higher Met levels and tHcy levels even
when adjusting for age at diagnosis. When adjusting for cur-
rent age, all results remained significant except for QoL.
Thus, current age explained the relationships between
screening time and QoL, but not those between screening
time and other factors.
In addition, late screening time significantly predicted
lower QoL and IQ, and higher Met and tHcy levels, even
when taking into account adherence.
This indicates that early screening is essential in
explaining psychological, cognitive, and biochemical out-
comes regardless of age at diagnosis, current age, and/or
adherence levels. Thus, additional factors can explain these
relationships. We can only speculate that, for example, fam-
ily awareness about the disease, early medical treatment or
socioeconomic status including educational levels of the par-
ents could explain these relationships. Further studies to
investigate these factors are needed.
Our results contribute to an improved understanding of
the natural history of HCU, supporting the effectiveness of
early diagnosis, especially by NBS, and dietary and pharma-
cological treatment compliance, for improving clinical out-
comes. With a mandatory and highly sensitive NBS in place,
the number of patients diagnosed late or through family
diagnosis should dwindle. As the NSG patients age, a future
age-matched comparison to this historical LDG cohort will
be possible.
In addition, these results suggest a need for new treat-
ment strategies, potentially leading to improved metabolic
control with a lessened requirement for diet compliance.
Consistent with our observations, existing treatment regi-
mens requiring life-long dietary restrictions make it chal-
lenging for patients to remain compliant, especially beyond
the childhood years.21-24 Thus, even with early diagnosis by
NBS and relatively high compliance, patients in our study
still developed some of the adverse clinical consequences of
their disease. Long-term cumulative exposure to elevated
tHcy levels may uncover additional sequelae not yet appar-
ent in the pediatric NSG cohort, and it may therefore be too
soon to ascertain whether long-term complications have
been avoided in this group, despite their abnormally high
tHcy levels.
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